Table 1 Baseline characteristics of patients and treatment.

From: The Role of Pretreatment Serum Neutrophil-to-Lymphocyte Ratio in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Pilot Study

Characteristics

Number (%)

Age (years)

<55

58 (48.3)

≥55

62 (51.7)

Sex

Male

117 (97.5)

Female

3 (2.5)

Performance status

0–1

105 (87.5)

≥2

15 (12.5)

BMI

<18.5

16 (13.3)

≥18.5

104 (86.7)

Comorbidity score

0–1

85 (70.8)

≥2

35 (29.2)

Smoking (pack-years)

<15

19 (22.1)

≥15

67 (77.9)

Tumour location

Pyriform sinus

97 (80.8)

Post-cricoid area

6 (5.0)

Posterior pharyngeal wall

17 (14.2)

Tumour differentiation

Grade 1–2

73 (60.8)

Grade 3

18 (15.0)

Unknown

29 (24.2)

Stage

I-II

5 (4.2)

III

15 (12.5)

IVA

81 (67.5)

IVB

19 (15.8)

Baseline NLR

<4

85 (70.8)

≥4

35 (29.2)

Treatment modality

CCRT

67 (55.8)

IC then CCRT or RT

53 (44.2)

RT treatment time (days)

<63

106 (88.3)

≥63

14 (11.7)

RT response

CR

63 (52.5)

Less than CR

57 (47.5)

  1. *BMI, body mass index; Hb, haemoglobin; neutrophil, absolute neutrophil count; lymphocyte, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; RT, radiotherapy; CR, complete response.
Back to article page